ExosoMe as Integrative Tool for pRognostic Stratification of Adverse Cardiac remodeLing in stEmi Patients: the MIRACLE Study

Last updated: October 2, 2023
Sponsor: Centro Cardiologico Monzino
Overall Status: Active - Recruiting

Phase

N/A

Condition

Angina

Myocardial Ischemia

Cardiac Ischemia

Treatment

CMR and blood collection

Clinical Study ID

NCT06070974
CCM 1931
  • Ages > 18
  • All Genders

Study Summary

This is a multicenter observational prospective study aimed to assess whether plasma exosomes can help identify, at an early stage, patients at high risk of adverse remodeling after STEMI (ST-elevation myocardial infarction) , thus accelerating proper patient management in order to reduce the risk of future cardiovascular events. In order to study the correlation between exosome profile and severity of myocardial infarction, consecutive STEMI patients will be enrolled 3 days after Percutaneous Coronary Intervention (PCI).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • chest pain suggestive of myocardial ischemia lasting >30 min
  • electrocardiogram (ECG) showing ST-segment elevation >0.1 mV in more or equal to 2limb leads or >0.2 mV in more or equal to 2 contiguous precordial leads, or presumednew left bundle-branch block
  • successful treatment with pPCI within 12 h from the onset of symptoms

Exclusion

Exclusion Criteria:

  • previous myocardial infarction (MI)
  • time to pPCI >12 h
  • atrial fibrillation
  • renal failure with glomerular filtration <30 ml/min
  • claustrophobia
  • other contraindications to CMR.

Study Design

Total Participants: 100
Treatment Group(s): 1
Primary Treatment: CMR and blood collection
Phase:
Study Start date:
May 03, 2023
Estimated Completion Date:
April 30, 2026

Study Description

Adverse cardiac remodeling is a process of structural and functional changes associated with worse clinical outcomes and increased mortality, which occurs in response to sustained pathophysiological stimuli, such as ST-elevation myocardial infarction (STEMI). Despite the progresses achieved with reperfusion therapy in STEMI, a significant portion of patients still develops adverse remodeling. Cardiovascular Magnetic Resonance (CMR) is the gold standard for clinical diagnosis of adverse remodeling, as it provides reliable and reproducible information on ventricular size, function and tissue damage. However, CMR is not always applicable, due to resources and availability reasons and to patients' contraindications. Therefore, additional markers for the early detection of patients at risk for adverse remodeling after STEMI are needed. Exosomes are small extracellular vesicles released by cells and detectable in all body fluids, including plasma. Their release and cargo are influenced by cellular microenvironment, thus mirroring cell/organ status. Previous study demonstrated that concentration and cargo of plasma exosomes released during STEMI well reflect the pathophysiology of the disease, suggesting their potential as biomarkers. Whether exosome profile analysis could predict adverse remodeling after STEMI remains to be investigated.

The relevant hypothesis to be tested is whether plasma exosomes may help to identify, in an early phase, patients at high risk of adverse remodeling after STEMI, accelerating proper patient management in order to reduce risk of further cardiovascular events and improve outcomes. Overall, this new knowledge will pave the way toward a new strategy to predict adverse remodeling in STEMI patients and to develop patient-tailored therapy.

Connect with a study center

  • IRCCS Centro Cardiologico Monzino

    Milano, Milan 20138
    Italy

    Active - Recruiting

  • Istituto Auxologico Italiano

    Milano, 20149
    Italy

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.